bz-423 has been researched along with African Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boitano, A; Ellman, JA; Glick, GD; Opipari, AW | 1 |
| Glick, GD; Ney, GM; Opipari, AW; Subramanian, C; Sundberg, TB | 1 |
2 other study(ies) available for bz-423 and African Lymphoma
| Article | Year |
|---|---|
The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells.
Topics: B-Lymphocytes; bcl-X Protein; Benzodiazepines; Burkitt Lymphoma; Cell Division; Cell Line, Tumor; Cell Survival; Humans; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Serum Albumin; Transfection | 2003 |
The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-myc protein for rapid and specific degradation.
Topics: B-Lymphocytes; Benzodiazepines; Biogenic Polyamines; Burkitt Lymphoma; Cell Cycle Proteins; Cell Growth Processes; Humans; Lymphocyte Activation; Mitochondrial Proton-Translocating ATPases; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-myc; Superoxides | 2006 |